Skip to Content
Merck
CN

28-4170

Sodium stearate

SAJ first grade, ≥96.0%

Synonym(s):

Octadecanoic acid sodium salt, Stearic acid sodium salt

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
CH3(CH2)16COONa
CAS Number:
822-16-2
Molecular Weight:
306.46
EC Number:
212-490-5
UNSPSC Code:
12352300
PubChem Substance ID:
329752908
Beilstein/REAXYS Number:
3576813
MDL number:
MFCD00036404

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C18H36O2.Na/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;/h2-17H2,1H3,(H,19,20);/q;+1/p-1

InChI key

RYYKJJJTJZKILX-UHFFFAOYSA-M

SMILES string

[Na+].CCCCCCCCCCCCCCCCCC([O-])=O

grade

SAJ first grade

assay

≥96.0%

form

solid

availability

available only in Japan

functional group

ester

storage temp.

room temp

Looking for similar products? Visit Product Comparison Guide

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
U2482
U6660
A7248
A1165

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert Damitz et al.
International journal of pharmaceutics, 486(1-2), 232-241 (2015-04-04)
Intravenous injections of propofol emulsions are accompanied by pain likely due to the interaction of the dissolved drug with endothelial cells of the vasculature. It is commonly hypothesized that reducing the aqueous phase concentration of propofol could reduce pain. To
T Aikawa et al.
Biomaterials science, 3(6), 861-869 (2015-07-30)
In order for patients to avail of the therapeutic benefits of antioxidant drugs efficiently and conveniently, a robust oral delivery system needs to be developed. However, a common problem in oral drug delivery is ensuring that the drug remains functionally
Luigi Battaglia et al.
Journal of pharmaceutical sciences, 103(7), 2157-2165 (2014-05-16)
The major obstacle to glioblastoma pharmacological therapy is the overcoming of the blood-brain barrier (BBB). In literature, several strategies have been proposed to overcome the BBB: in this experimental work, solid lipid nanoparticles (SLN), prepared according to fatty acid coacervation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service